HIGHLIGHTS
- who: Rongbo Lin from the Amadori", Italy University, China have published the article: POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial, in the Journal: (JOURNAL)
- what: The aim of this study is to prove the superiority of POF over SOX/CAPOX/FOLFOX in postoperative adjuvant setting for pathological stage III gastric adenocarcinoma (including adenocarcinoma of the gastroesophageal junction). With a statistical power of 80%, a two-sided α error of 5%, and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.